Biomedical Engineering Reference
In-Depth Information
References
Acemoglu D, Linn J (2004) Market size in innovation: theory and evidence from the pharmaceuti-
cal industry. Quart J Econ 119(3):1049-1090
Angell M (2004) Excess in the pharmaceutical industry. Can Med Assoc J 171(12):1451-1453
Arora A, Gambardella A, Magazzini L, Pammolli F (2007) A breath of fresh air? Firm type, scale,
scope and selection effects in drug development, working paper
Bottazzi G, Dosi G, Lippi M, Pammolli F, Riccaboni M (2001) Innovation and corporate growth in
the evolution of the drug industry. Int J Ind Organ 19:1161-1187
Cassiman B, Ueda M (2006) Optimal project rejection and new fi rm start-ups. Manag Sci
52(2):262-275
Chan T, Nickerson JA, Owan H (2007) Strategic management of R&D pipelines with co-specialized
investments and technology markets. Manag Sci 53(4):667-682
Chandy R, Hopstaken B, Narasimhan O, Prabhu J (2006) From invention to innovation: conver-
sion ability in product development. J Market Res XLIII:494-508
Cockburn IM (2007) Is the pharmaceutical industry in a productivity crisis? In: Lerner J, Stern S
(eds) Innovation policy and the economy, vol 7. NBER, MIT Press, Cambridge
Cockburn IM, Henderson RM (1996) Public-private interaction in pharmaceutical research. Proc
Natl Acad Sci 93:12725-12730
Cockburn IM, Henderson RM (1998) Absorptive capacity, coauthoring behavior, and the organiza-
tion of research in drug discovery. J Ind Econ 46(2):157-182
Cockburn IM, Henderson RM (2001a) Publicly funded science and the productivity of the pharma-
ceutical industry. In: Jaffe A, Lerner J, Stern S (eds) Innovation policy and the economy, vol 1.
NBER, MIT Press, Cambridge
Cockburn IM, Henderson RM (2001b) Scale and scope in drug development: unpacking the
advantages of size in pharmaceutical research. J Health Econ 20:1033-1057
Cohen WM, Levintal DA (1989) Innovation and learning: the two faces of R&D. Econ J
99:569-596
Cohen WM, Levintal DA (1990) Absorptive capacity: a new perspective on learning and innova-
tion. Adm Sci Q 35(1):128-152
Danzon PM, Nicholson S, Pereira NS (2005) Productivity in pharmaceutical-biotechnology R&D:
the role of experience and alliances. J Health Econ 24:317-339
Deeds DL, Hill CWL (1996) Strategic alliances and the rate of new product development: an
empirical study of entrepreneurial biotechnology fi rms. J Bus Venturing 11:41-55
DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: is biotech different?
Manag Decis Econ 28:469-479
DiMasi JA, Paquette C (2004) The economics of follow-on drug research and development: trends
in entry rates and the timing of development. Pharmacoeconomics 22:1-14
DiMasi J, Grabowski HG, Vernon J (1995) R&D costs, innovative output and fi rm size in the phar-
maceutical industry. Int J Econ Bus 2(2):201-219
DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug
development costs. J Health Econ 22:151-185
Ding M, Eliashberg J (2002) Structuring the new product development pipeline. Manag Sci
48(3):343-363
Ding M, Eliashberg J (2008) A dynamic competitive forecasting model incorporating dyadic deci-
sion making. Manag Sci 54(4):820-834
Gans JS, Stern S (2000) Incumbency and R&D incentives: licensing the gale of creative destruc-
tion. J Econ Manag Strat 9(4):485-511
Gassmann O, Reepmeyer G (2005) Organizing pharmaceutical innovation: from science-based
knowledge creators to drug-oriented knowledge brokers. Creativity Innov Manag
14(3):233-245
Gassmann O, von Zedtwitz M (1998) Organization of industrial R&D on a global scale. R&D
Manag 28(3):147-161
Search WWH ::
Custom Search